Portrait of Christian Bogner, M.D


Christian Bogner, M.D is fighting to show the world the benefits of Medical Cannabis for the Autism Spectrum. He is also the author of “The Endocannabinoid System as it Relates to Autism” and Medical Jane contributor including the 3 part series published on MedicalJane.

His interest lies in strain research, specifically pioneering correct ratios for the wide spectrum of ASD.

Dr. Bogner, along with his Detroit based attorney Michael Komorn and researcher Joe Stone are fighting to add Autism as a qualifying condition for the medical Cannabis program in Michigan. The vote is July 20th. A yes vote would be the first in the country and potentially revolutionize the way we look at Autism.

His work is actively advocated by Lester Grinspoon, MD and many other experts in the field of neuropsychiatric research.
Follow him on Facebook at “Let it grow for Autism”.

In The News

image for article

July 28, 2015

Michigan Medical Marijuana Review Panel Denies Overwhelming Research Proving Cannabis is a Medicine
Residents in Michigan may submit medical conditions to LARA in order for the Michigan Medical Marihuana Review Panel to review whether there is ample evidence that cannabis may have palliative relief in the treatment of that condition. It is the voter’s intent to protect those with debilitating medical conditions that may receive palliative relief from cannabis. When the panel is provided sufficient evidence it is their mandate to ensure that new medical conditions be added to the list of qualifying conditions for medical cannabis. In 2012 Jenny Allen, the mother of an autistic child, petitioned LARA to …
image for article

June 17, 2015

Part Three: Practical Approach to Cannabis Based ASD Therapies
In our previous installment, we provided a brief overview of the preclinical research implicating the role that the endocannabinoid system (ECS) plays in the progression of autism spectrum disorder (ASD), preclinical research supporting targeting the ECS to treat ASD, and provided a number of preclinical studies indicating the potential value of phytocannabinoids in treating symptoms and diseases associated with ASD. Here we’ll examine the shortcomings of current research, explore possible adverse effects of cannabinoid treatments, discuss the types of autism that may currently warrant cannabinoid treatments, and illustrate how a family might systematically approach a cannabinoid treatment for …
image for article

June 17, 2015

Part Two: The Role of Phytocannabinoids in ASD Therapy
In part one of this series the preclinical scientific evidence illustrating the involvement of the endocannabinoid system (ECS) in the physiological progression of Autism Spectrum Disorder (ASD) was provided. Here we’ll highlight some of the pharmacological characteristics that phytocannabinoids share with endocannabinoids, the use of phytocannabinoids in the treatment of symptoms and diseases associated with ASD, and why having access to a variety of cannabis chemotypes will always be preferable to a select cannabinoid and/or ratio. The anecdotal reports of successful cannabinoid therapies seem to be supported by the fact that phytocannabinoids from cannabis, and other natural sources, …
image for article

June 17, 2015

Part One: The Endocannabinoid System and Autism Spectrum Disorder (ASD)
The importance of the discovery of the role that the endocannabinoid system (ECS) plays in human health and disease cannot be understated. Cannabinoid receptors are the most highly expressed of any G-protein coupled receptor (GPCR) in the body. They’re the only ones to play a direct role in virtually every aspect of the human body (CNS and immune systems, throughout the periphery, presynaptic, and postsynaptic).[1] It’s no wonder that anecdotal reports of cannabis treatments indicate effectiveness in such a wide array of conditions. The growing body of scientific research …

DISCLAIMER: The professionals and companies described are not associated or affiliated with Medical Jane, and they may not endorse Medical Jane or the information provided. The names of other companies, products and services are the property of their respective owners.